8.3. summary evidence recommendations surveillance following rn pn ablative therapies rcc. summary evidencelefunctional follow-up curative treatment rcc useful prevent renal cardiovascular deterioration.4oncological follow-up detect local recurrence metastatic disease patient may still surgically curable.4after nss, increased risk recurrence larger (> 7 cm) tumours, psm.3patients undergoing follow-up better os patients undergoing follow-up.3prognostic models provide stratification rcc risk recurrence based tnm histological features.3in competing-risk models, risk non-rcc-related death exceeds rcc recurrence related death low-risk patients.3life expectancy estimation feasible may support counselling patients duration follow-up.4overall survival reduced metastatic rcc patients symptoms depression distress.2a recommendationsstrength ratingbase follow-up treatment localised rcc risk recurrence.strongbase risk recurrence stratification validated subtype-specific models leibovich score clear cell renal cell carcinoma (ccrcc), university california los angeles integrated staging system non-ccrcc.weakintensify follow-up patients nephron-sparing surgery tumours > 7 cm patients positive surgical margin.weakconsider curtailing follow-up risk dying causes double rcc recurrence risk.weakoffer psychological evaluation patients diagnosed rcc provide timely support distress, depression, anxiety.weak